We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
The current CRTHF market cap is 437.49M. The company's latest EPS is CNY -1.2991 and P/E is -0.59.
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| CNY (元) | CNY (元) | CNY (元) | CNY (元) | CNY (元) | |
| Total Revenue | 0 | 0 | 25.81M | 0 | 0 |
| Operating Income | -230.36M | -348.67M | -585.99M | -802.2M | -784.68M |
| Net Income | -265.13M | -1.06B | -4.74B | -892.25M | -747.79M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| CNY (元) | CNY (元) | CNY (元) | CNY (元) | CNY (元) | |
| Total Assets | 325.81M | 1.25B | 3.51B | 2.76B | 2.26B |
| Total Liabilities | 1.06B | 2.93B | 508.98M | 289.65M | 455.51M |
| Total Equity | -732.6M | -1.68B | 3B | 2.47B | 1.8B |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| CNY (元) | CNY (元) | CNY (元) | CNY (元) | CNY (元) | |
| Operating | -179M | -295.15M | -512.32M | -643.05M | -454.94M |
| Investing | 82.99M | -6.9M | -2.47B | 2.39B | 39.25M |
| Financing | 27.53M | 1.3B | 2.67B | -236.51M | -22.14M |
| Market Cap | 437.49M |
| Price to Earnings Ratio | -0.59 |
| Price to Sales Ratio | 0 |
| Price to Cash Ratio | 0.24 |
| Price to Book Ratio | 0.24 |
| Dividend Yield | - |
| Shares Outstanding | 575.64M |
| Average Volume (1 week) | 0 |
| Average Volume (1 Month) | 0 |
| 52 Week Change | -54.49% |
| 52 Week High | 1.67 |
| 52 Week Low | 0.7465 |
| Spread (Intraday) | 0.12 (9.09%) |
| Company Name | CARsgen Therapeutics Holdings Ltd (PK) |
| Address |
bldg 12 shanghai |
| Website | https://www.carsgen.com |
| Industry | offices of medical doctors (8011) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
